Pfizer Vyndaqel Launch Surprises With An Early Burst Out Of The Gate

The drug outperformed investor expectations, generating $79m in the US in its first full quarter on the market, after Pfizer had set low expectations for the initial launch.

High-energy particles explosion. 3D illustration - Illustration — The launch of Vyndaqel started with a bang. • Source: Shutterstock

Pfizer Inc.'s new rare disease franchise Vyndaqel/Vyndamax (tafamidis) got off to a strong start, surprising investors by generating notable revenues in its first full quarter on the market. Management had set low expectations for initial uptake of the first-in-class transthyretin stabilizer, indicated for treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), because of low diagnosis rates.

Vyndaqel generated $79m in the US and $156m worldwide, the company reported in its third quarter financial report on 29...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

02 Jul 2025

• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

Pipeline Watch: Eleven Approvals And ADA Readouts Dominate

30 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Empty Promises: Five Drugs That Fell Short Of Their Sales Forecasts

30 Jun 2025

• By Edwin Elmhirst

Many assets underperform their pre-launch sales predictions, which can be disastrous to their developers and marketers. In this article, Scrip highlights several historic examples and the factors that influenced their poorer-than-expected performance.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

23 Jun 2025

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

02 Jul 2025

• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.